Literature DB >> 18596683

Dosing algorithms to predict warfarin maintenance dose in Caucasians and African Americans.

H Schelleman1, J Chen, Z Chen, J Christie, C W Newcomb, C M Brensinger, M Price, A S Whitehead, C Kealey, C F Thorn, F F Samaha, S E Kimmel.   

Abstract

The objective of this study was to determine whether warfarin dosing algorithms developed for Caucasians and African Americans on the basis of clinical, environmental, and genetic factors will perform better than an empirical starting dose of 5 mg/day. From April 2002 through December 2005, 259 subjects (Caucasians and African Americans) who started using warfarin were prospectively followed until they reached maintenance dose. The Caucasian algorithm included 11 variables (R(2) = 0.43). This model (which predicted 51% of the doses to within 1 mg of the observed dose) performed better than 5 mg/day (which predicted 29% of the doses to within 5 +/- 1 mg). The African-American algorithm included 10 variables (R(2) = 0.28). This model predicted 37% of the doses to within 1 mg of the observed dose, representing a small improvement compared with 5 mg/day (which predicted 34% of the doses to within 1 mg of 5 mg/day). These results were similar to the results we obtained from testing other published algorithms. The dosing algorithms explained <45% of the observed variability in Caucasians, and the algorithms performed only marginally better for African Americans when compared with giving 5 mg empirically.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18596683      PMCID: PMC2538606          DOI: 10.1038/clpt.2008.101

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  36 in total

1.  Main haplotypes and mutational analysis of vitamin K epoxide reductase (VKORC1) in a Swedish population: a retrospective analysis of case records.

Authors:  A Osman; C Enström; K Arbring; P Söderkvist; T L Lindahl
Journal:  J Thromb Haemost       Date:  2006-08       Impact factor: 5.824

2.  Multiplex PCR amplification from the CFTR gene using DNA prepared from buccal brushes/swabs.

Authors:  B Richards; J Skoletsky; A P Shuber; R Balfour; R C Stern; H L Dorkin; R B Parad; D Witt; K W Klinger
Journal:  Hum Mol Genet       Date:  1993-02       Impact factor: 6.150

3.  Prospective evaluation of a flexible protocol for starting treatment with warfarin and predicting its maintenance dose.

Authors:  D G Cosh; C K Moritz; K J Ashman; R J Dally; A S Gallus
Journal:  Aust N Z J Med       Date:  1989-06

4.  Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype.

Authors:  Deepak Voora; Charles Eby; Mark W Linder; Paul E Milligan; Bonny L Bukaveckas; Howard L McLeod; William Maloney; John Clohisy; R Steven Burnett; Leonard Grosso; Susan K Gatchel; Brian F Gage
Journal:  Thromb Haemost       Date:  2005-04       Impact factor: 5.249

5.  Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans.

Authors:  Harumi Takahashi; Grant R Wilkinson; Edith A Nutescu; Takashi Morita; Marylyn D Ritchie; Maria G Scordo; Vittorio Pengo; Martina Barban; Roberto Padrini; Ichiro Ieiri; Kenji Otsubo; Toshitaka Kashima; Sosuke Kimura; Shinichi Kijima; Hirotoshi Echizen
Journal:  Pharmacogenet Genomics       Date:  2006-02       Impact factor: 2.089

6.  Monitoring warfarin therapy in patients with lupus anticoagulants.

Authors:  S Moll; T L Ortel
Journal:  Ann Intern Med       Date:  1997-08-01       Impact factor: 25.391

7.  Management of venous thromboembolism: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians.

Authors:  Vincenza Snow; Amir Qaseem; Patricia Barry; E Rodney Hornbake; Jonathan E Rodnick; Timothy Tobolic; Belinda Ireland; Jodi B Segal; Eric B Bass; Kevin B Weiss; Lee Green; Douglas K Owens
Journal:  Ann Intern Med       Date:  2007-01-29       Impact factor: 25.391

8.  The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

Authors:  Jack Ansell; Jack Hirsh; Leon Poller; Henry Bussey; Alan Jacobson; Elaine Hylek
Journal:  Chest       Date:  2004-09       Impact factor: 9.410

9.  Factors affecting the maintenance dose of warfarin.

Authors:  A H James; R P Britt; C L Raskino; S G Thompson
Journal:  J Clin Pathol       Date:  1992-08       Impact factor: 3.411

Review 10.  The epidemiology of venous thromboembolism.

Authors:  Richard H White
Journal:  Circulation       Date:  2003-06-17       Impact factor: 29.690

View more
  60 in total

1.  Genetic warfarin dosing: tables versus algorithms.

Authors:  Brian S Finkelman; Brian F Gage; Julie A Johnson; Colleen M Brensinger; Stephen E Kimmel
Journal:  J Am Coll Cardiol       Date:  2011-02-01       Impact factor: 24.094

2.  The missing association: sequencing-based discovery of novel SNPs in VKORC1 and CYP2C9 that affect warfarin dose in African Americans.

Authors:  M A Perera; E Gamazon; L H Cavallari; S R Patel; S Poindexter; R A Kittles; D Nicolae; N J Cox
Journal:  Clin Pharmacol Ther       Date:  2011-01-26       Impact factor: 6.875

3.  Decreased warfarin clearance associated with the CYP2C9 R150H (*8) polymorphism.

Authors:  Y Liu; H Jeong; H Takahashi; K Drozda; S R Patel; N L Shapiro; E A Nutescu; L H Cavallari
Journal:  Clin Pharmacol Ther       Date:  2012-02-29       Impact factor: 6.875

4.  Integration of genetic, clinical, and INR data to refine warfarin dosing.

Authors:  P Lenzini; M Wadelius; S Kimmel; J L Anderson; A L Jorgensen; M Pirmohamed; M D Caldwell; N Limdi; J K Burmester; M B Dowd; P Angchaisuksiri; A R Bass; J Chen; N Eriksson; A Rane; J D Lindh; J F Carlquist; B D Horne; G Grice; P E Milligan; C Eby; J Shin; H Kim; D Kurnik; C M Stein; G McMillin; R C Pendleton; R L Berg; P Deloukas; B F Gage
Journal:  Clin Pharmacol Ther       Date:  2010-04-07       Impact factor: 6.875

5.  Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups.

Authors:  Stuart A Scott; Rame Khasawneh; Inga Peter; Ruth Kornreich; Robert J Desnick
Journal:  Pharmacogenomics       Date:  2010-06       Impact factor: 2.533

6.  Exploring warfarin pharmacogenomics with the extreme-discordant-phenotype methodology: impact of FVII polymorphisms on stable anticoagulation with warfarin.

Authors:  Mateus Fuchshuber-Moraes; Jamila A Perini; Dieter Rosskopf; Guilherme Suarez-Kurtz
Journal:  Eur J Clin Pharmacol       Date:  2009-04-23       Impact factor: 2.953

7.  A pharmacogenetics service experience for pharmacy students, residents, and fellows.

Authors:  Katarzyna Drozda; Yana Labinov; Ruixuan Jiang; Margaret R Thomas; Shan S Wong; Shitalben Patel; Edith A Nutescu; Larisa H Cavallari
Journal:  Am J Pharm Educ       Date:  2013-10-14       Impact factor: 2.047

Review 8.  The future of warfarin pharmacogenetics in under-represented minority groups.

Authors:  Larisa H Cavallari; Minoli A Perera
Journal:  Future Cardiol       Date:  2012-07

9.  High-dimensional pharmacogenetic prediction of a continuous trait using machine learning techniques with application to warfarin dose prediction in African Americans.

Authors:  Erdal Cosgun; Nita A Limdi; Christine W Duarte
Journal:  Bioinformatics       Date:  2011-03-30       Impact factor: 6.937

10.  VKORC1-1639A allele influences warfarin maintenance dosage among Blacks receiving warfarin anticoagulation: a retrospective cohort study.

Authors:  Fatima Donia Mili; Tenecia Allen; Paula Weinstein Wadell; W Craig Hooper; Christine De Staercke; Christopher J Bean; Cathy Lally; Harland Austin; Nanette K Wenger
Journal:  Future Cardiol       Date:  2017-12-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.